WebJul 11, 2024 · Age-adjusted COPD death rates in adults aged ≥ 45 years varied between states in 2024 and ranged from 44.5 per 100,000 in Hawaii to 174.6 per 100,000 in Kentucky. Age-adjusted Death Rate (per 100,000) 44.5 - 94.0. 94.1 - 108.0. 108.1 - 132.8. WebSociodemographic and clinical characteristics of 1,263 COPD patients tabulated by an inhaler device are shown in Table 1. A total of 38.95% of patients used a pMDI and 61.05% used a DPI during the time of study. The mean age of patients was 71 years, most of them were retired (88.44%), and 83.45% of them were men.
Cardiothoracic Ratio - an overview ScienceDirect Topics
WebSep 19, 2024 · Results: The 45350 eligible patients included 25% A0, 4% A1, 44% B0, 10% B1, and 17% E. Moderate exacerbations, all-cause and respiratory hospitalizations, and all-cause and respiratory mortality increased by GOLD group A0-A1-B0-B1-E, except for moderate exacerbations which was higher in A1 than B0. WebThis study compared the validated COPD treatment ratio (CTR) versus other COPD exacerbation predictors: prior exacerbation and rescue and maintenance medication use. Methods: A retrospective observational study using medical and pharmacy claims … Past Issues - COPD Treatment Ratio and Severe Exacerbation Risk Journal of … Articles In Press - COPD Treatment Ratio and Severe Exacerbation Risk Journal … Free Subscription - COPD Treatment Ratio and Severe Exacerbation Risk Journal … Submit a Manuscript - COPD Treatment Ratio and Severe Exacerbation Risk … i\u0027m big billy cat video
PQA Developing Health Plan Measure for COPD Treatment Ratio
WebJul 12, 2024 · Introduction. Lower respiratory infections, including chronic obstructive pulmonary disease (COPD) and pneumonia, are a leading cause of morbidity and mortality worldwide. 1 A previous large cohort study revealed that up to 36% of patients with COPD exacerbation also have pneumonia and that several of the important clinical outcomes of … WebJan 18, 2024 · Investigators found that use of a COPD treatment ratio (CTR) has been shown to provide a modifiable measure of risk of COPD exacerbation in a large commercial and Medicare population, and remained a strong predictor in circumstances when pharmacy-only data claims were available. WebEmail [email protected]. Background: COPD prevalence and mortality in Kyrgyzstan are high. Data on clinical and economic impact of COPD in Kyrgyzstan are scarce. This study was part of the FRESH AIR research project that focused on prevention, diagnosis and treatment of chronic lung diseases in low-resource settings. i\u0027m big now learning center